Healthcare >> Sector Roundtables >> October 1, 2001

Roundtable Forum: Biotechnology Industry

MICHAEL G. KING, JR. is a Managing Director and Senior Biotechnology Analyst at Robertson Stephens. He focuses on the genomics sector. Prior to joining Robertson Stephens he was a Senior Biotechnology Analyst at Vector Securities International and served as Vice President of Research, Biotechnology, with Dillon, Read & Co., Inc. Mr. King also has been a Senior Vice President of Sales at Alex. Brown and Sons. In 2001, he ranked fourth for his stock-picking accuracy in The Wall Street Journal's annual 'Best on the Street' survey. In 2000, Mr. King was given the Institutional Investor Home Run Hitter award for his coverage of OSI Pharmaceuticals. He holds a BBA degree from Baruch College. Profile
ELISE T. WANG is currently a Managing Director in Equity Research at Salomon Smith Barney covering the biotechnology industry. Previously, she was a Managing Director and Senior Research Analyst in the Health Care Equity Research Group at PaineWebber Incorporated, covering the biotechnology industry. In 2000, Ms. Wang was voted runner-up in the Institutional Investor poll in Biotechnology. In addition, Ms. Wang also achieved recognition in the Wall Street Journal All Star Analyst survey in Biotechnology for the past three years. Prior to joining Equity Research at PaineWebber in January of 1996, she was a Vice President in the Health Sciences Group of the Investment Banking Division of PaineWebber with responsibility for providing financial advisory work and services in biotechnology and other healthcare sectors. Ms. Wang holds a Bachelor of Arts degree in Engineering Sciences with a specialty in Biomechanics from Harvard University and a Master of Business Administration degree from Harvard Graduate School of Business. Profile
DR. PETER F. DRAKE is a Managing Director and Senior Biotechnology Analyst at Prudential Securities, Inc. He was a co-Founder and Executive Vice President of Vector Securities International, Inc., which was acquired in July 1999 by Prudential Securities, Inc. Prior to this, Dr. Drake was a Partner with Kidder Peabody and Company and was its Senior Research Analyst covering biotechnology and biomedical products from 1980-1983. Dr. Drake has published extensively on the biotechnology industry. He has been consistently ranked among the leading analysts on Wall Street by Institutional Investor magazine most recently as the number one analyst among regional research boutiques, while at Vector Securities International Inc. 1995-1999. Dr. Drake holds a PhD in Neurobiology and Biochemistry from Bryn College, and a CBA from the Wharton School of Business at the University of Pennsylvania, and performed his undergraduate work at Bowdoin College where he majored in Biology and Russian. Profile
DR. MARY ANN GRAY has been with the Federated Kaufmann Fund for the past two years, focusing on both public and private healthcare investments. Prior to joining the Kaufmann Fund, Dr. Gray was a sell side Biotechnology Analyst for nine years with Kidder Peabody; Dillon, Read; and Raymond James. Earlier in her career, Dr. Gray managed preclinical toxicology studies for the National Cancer Institute through Battelle Memorial Institute and worked in a hospital laboratory. She did postdoctoral work at Northwestern University Medical School and Yale University School of Medicine. She held scientific positions at Schering-Plough and NeoRx. Dr. Gray has a PhD in Pharmacology from the University of Vermont where she focused on novel chemotherapeutic agents for the treatment of cancer. Profile
TWST: Elise, how has the biotechnology industry evolved over the past

several years? What are the sectors that should be included in a

discussion of biotechnology today?

Ms. Wang: An important